Regeneron Pharmaceuticals Inc (WBO:REGN)
€ 757.4 -20.4 (-2.62%) Market Cap: 83.82 Bil Enterprise Value: 77.30 Bil PE Ratio: 20.53 PB Ratio: 3.11 GF Score: 99/100

Regeneron Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference Transcript

Jun 14, 2022 / 03:40PM GMT
Release Date Price: €527.5 (-0.68%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Great. Good morning. Thanks, everyone, for joining us. Really pleased to have the Regeneron team with us. We have Bob Landry, CFO; and we have Marion McCourt, Head of Commercial; and Ryan Crowe, Investor Relations. With that, Ryan, I'm going to turn it over to you.

Ryan Crowe
Regeneron Pharmaceuticals, Inc. - VP of IR

Thanks Salveen. Great to be here. Just wanted to remind everyone that today's presentation will include forward-looking statements about Regeneron and actual results may differ materially from those presented in those forward-looking statements. A full recital of risks and uncertainties associated with Regeneron can be found in our SEC filings located on our website.

With that, over to Salveen.

Robert E. Landry
Regeneron Pharmaceuticals, Inc. - Executive VP of Finance & CFO

Salveen, I was going to do some just introductory comments, kind of fill people in on where we've been in the first half of the year. As you

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot